Biosimilars of anti-TNF-α inhibitors have become a valid and usually less expensive alternative to their originator drugs [1]. Therefore, switching from originator to biosimilar drugs is an increasingly widespread approach because of the potential cost savings. As more biosimilars become available, switching between biosimilars of the same originator will be likely.

Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis

Conti, Andrea;Bellinato, Francesco;Gisondi, Paolo
2021-01-01

Abstract

Biosimilars of anti-TNF-α inhibitors have become a valid and usually less expensive alternative to their originator drugs [1]. Therefore, switching from originator to biosimilar drugs is an increasingly widespread approach because of the potential cost savings. As more biosimilars become available, switching between biosimilars of the same originator will be likely.
2021
psoriasis, etanercept, biosimilar
File in questo prodotto:
File Dimensione Formato  
Cross‑Switch from Etanercept Originator to Biosimilar SB4.pdf

accesso aperto

Licenza: Dominio pubblico
Dimensione 417.6 kB
Formato Adobe PDF
417.6 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1087012
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact